CTOs on the Move

MedPharm

www.medpharm.com

 
MedPharm is a world-leading contract provider of topical and transdermal product design and development services. Our delivery of robust and innovative research has commanded recognition from regulators and investors alike. We utilise our unique cost-effective performance testing models to mitigate risk and accelerate development times.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.medpharm.com
  • 4222 Emperor Boulevard Suite 335
    Durham, NC USA 27703
  • Phone: 919.436.4985

Executives

Name Title Contact Details
Dave Haas
Vice President Information Technology Profile
Jon Lenn
Chief Technology Officer and Chief Scientific Officer Profile

Similar Companies

TearScience

TearScience is a Morrisville, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Purdue Pharma L.P.

Purdue Pharma LP is a privately held pharmaceutical company founded by John Purdue Gray.

Integrated Project Services

IPS-Integrated Project Services, LLC is a global leader in developing innovative solutions for the consulting, architecture, engineering, project controls, construction management, and CQV of technically complex facilities worldwide. With technical expertise spanning R&D to pilot-scale to large-scale production, our team specializes in the technology, trends, and regulatory environment to successfully deliver capital projects and improve operations.

Radionetics

Radionetics Oncology is a pharmaceutical company focused on the discovery and development of novel radiotherapeutics for the treatment of a wide range of oncology indications. The company`s platform technology uses nonpeptide, small molecule targeting to deliver therapeutic radioisotopes to a broad range of cancers by binding selectively to peptide receptors that are selectively expressed on these tumors. This nonpeptide technology addresses many of the significant challenges currently facing peptide and protein targeted radiotherapeutics, particularly in the realm of optimizing drug-like characteristics and manufacturing. The company is rapidly advancing a pipeline of drug candidates to treat a broad range of cancers and is conducting additional drug discovery efforts to identify drug candidates for additional receptor targets in collaboration with Crinetics Pharmaceuticals.